Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A completely new treatment for diabetic retinopathy has started being tested in people for the first time. The first-in-man trials of experimental drug KVD001 began this month, focussing on assessing the safety and tolerability of the drug in treating diabetic macular oedema (a particular type of retinopathy).
The trials are being conducted at the world renowned Beetham Eye Institute (part of the Joslin Diabetes Centre at Harvard Medical School in Boston) and recruitment will gradually roll out through five centres in the US.
The company behind the drug, KalVista, is a small biotechnology company based near Southampton. JDRF has been working with KalVista on the drug for a number of years, and indeed JDRF supported the academic research that identified the biological pathway the drug is designed to target.
http://www.jdrf.org.uk/news/latest-...for-diabetic-retinopathy-hits-clinical-trials
The trials are being conducted at the world renowned Beetham Eye Institute (part of the Joslin Diabetes Centre at Harvard Medical School in Boston) and recruitment will gradually roll out through five centres in the US.
The company behind the drug, KalVista, is a small biotechnology company based near Southampton. JDRF has been working with KalVista on the drug for a number of years, and indeed JDRF supported the academic research that identified the biological pathway the drug is designed to target.
http://www.jdrf.org.uk/news/latest-...for-diabetic-retinopathy-hits-clinical-trials